Feline CKD: Hypoxia Response, Iron Handling, and Lipid Oxygenation

Chronic kidney disease (CKD) remains one of the most common and clinically significant conditions in older cats. While its clinical progression is well recognized, the molecular underpinnings—particularly in the renal cortex—are less clearly defined. A recent secondary analysis of public feline renal RNA-seq data (GSE303653) provides new perspectives on how hypoxia response, iron handling, and lipid oxygenation interact at the transcript level.

Study Design

This analysis was guided by a pre-set internal plan, focusing on a fixed 23-gene panel alongside whole-transcriptome evaluation. After rigorous quality control, 21 renal cortex samples spanning control, CKD stages 1/2, and CKD stages 3/4 were included. Likelihood ratio testing served as the primary inferential tool, with secondary analyses (pairwise contrasts, enrichment, composites, and marker sets) providing context.

Key Findings

• VEGFA, FTL, and NCOA4 transcripts decreased progressively with disease stage.
• ALOX5 and HIF1A increased with advancing CKD.
• Eight genes in the panel showed significant stage-association by likelihood ratio testing.
• The equal-weight composite score was nonmonotonic, suggesting heterogeneous remodeling rather than a simple linear progression.
• Advanced CKD enrichment was dominated by immune and inflammatory pathways, while GPX4 and ferroptosis-related signals were not stage-significant.

Interpretation for Clinical Context

The data highlight a divergence between HIF1A and VEGFA, pointing to altered hypoxia signaling in feline CKD. The increase in ALOX5 suggests a role for lipid oxygenation and inflammatory signaling, potentially contributing to disease progression. Importantly, despite transcript-level changes in iron-handling genes (FTL, NCOA4), there was no evidence of ferroptotic cell death or pathway activation.

This implies that while oxidative and inflammatory remodeling is evident, ferroptosis is unlikely to be a dominant mechanism in feline CKD progression. Instead, the transcriptome reflects a heterogeneous response, with immune activation and altered hypoxia signaling at the forefront.

Practical Takeaways for Veterinarians

• CKD progression in cats involves complex transcript-level remodeling rather than a single pathway.
• Inflammatory and lipid oxygenation signals (ALOX5) may represent emerging therapeutic or biomarker targets. More specific studies can lead to noticeable results.
• Hypoxia signaling divergence (HIF1A vs VEGFA) underscores the need to consider microvascular and oxygenation dynamics in feline CKD management.
• Iron handling changes are evident but do not translate into ferroptotic pathway activation, suggesting caution in overinterpreting iron-related interventions.

Conclusion

For practicing veterinarians, these findings reinforce the multifactorial nature of feline CKD. Beyond the well-known clinical signs, transcript-level data reveal nuanced remodeling—particularly in hypoxia and inflammatory pathways—that may inform future diagnostics and therapies.